Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 708 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IT Injection Clear all
Not listed Not applicable Interventional

Medial Versus Traditional Approach to US-guided TAP Blocks for Open Inguinal Hernia Repair

NCT01589796
View directory record Official record
Conditions
Abdominal Muscles/Ultrasonography, Adult, Ambulatory Surgical Procedures, Anesthetics, Local/Administration & Dosage, Ropivacaine/Administration & Dosage, Ropivacaine/Analogs & Derivatives, Hernia, Inguinal/Surgery, Humans, Nerve Block/Methods, Pain Measurement/Methods, Pain, Postoperative/Prevention & Control, Ultrasonography, Interventional
Interventions
TAP block
Procedure
Lead sponsor
Stamford Anesthesiology Services, PC
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Phase 1 Interventional Results available

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

NCT03154294
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
paclitaxel, TAK-228, TAK-117
Drug
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Not applicable Interventional

Strength Testing After Nitrate Delivery (STAND) in ICU Patients

NCT02293616
View directory record Official record
Conditions
Respiratory Failure
Interventions
Nitrate Rich Beetroot Juice, Placebo
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
56 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 22, 2026, 9:20 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

NCT07075640
View directory record Official record
Conditions
Healthy Participants
Interventions
AG-236, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

NCT04740476
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen (STK-001)
Drug
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
30 Months and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Pilot Trial: Comparing Buzzy to Intradermal Lidocaine for Peripheral IV Cannulation in Adults

NCT04647084
View directory record Official record
Conditions
Pain, Acute, Patient Satisfaction
Interventions
Lidocaine 2% Injectable Solution, Buzzy
Drug · Device
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies

NCT03961555
View directory record Official record
Conditions
Rabies
Interventions
SYN023, HRIG (HyperRab), Rabies vaccine
Biological
Lead sponsor
Synermore Biologics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • Milan, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

NCT01949155
View directory record Official record
Conditions
Otitis Media With Effusion
Interventions
OTO-201, Sham
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Not applicable Interventional

Ultrasound-guided Transgluteal Sciatic Nerve Hydrodissection for the Treatment of Sciatica in the Emergency Department

NCT07588126
View directory record Official record
Conditions
Sciatica Acute, Sciatica Pain
Interventions
Ultrasound guided transgluteal sciatic nerve hydrodissection
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Phase 2 Interventional

Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military

NCT04274543
View directory record Official record
Conditions
Tibial Meniscus Injuries, Knee Injuries, Knee Injuries and Disorders
Interventions
Lipogems, Normal Saline
Device · Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalation PfSPZ-CVac

NCT03083847
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 22, 2026, 9:20 AM EDT
Recruiting Phase 1 Interventional

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT03571321
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions
Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

NCT01984892
View directory record Official record
Conditions
Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
Interventions
Poly-ICLC
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
14 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Not applicable Interventional Results available

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes

NCT03093636
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Continuous Glucose Monitor (CGM)+Decision Support System (DSS), Continuous Glucose Monitor (CGM) alone
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
15 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Stanford, California • New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 22, 2026, 9:20 AM EDT
Active, not recruiting Phase 3 Interventional

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

NCT06914609
View directory record Official record
Conditions
Angelman Syndrome
Interventions
obudanersen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 50 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Active, not recruiting No phase listed Observational

Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT

NCT03846167
View directory record Official record
Conditions
Breast Cancer
Interventions
Imaging Drug FluorThanatrace (FTT)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

NCT00004635
View directory record Official record
Conditions
Prostate Cancer
Interventions
Thalidomide, leuprolide acetate, goserelin, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
9
States / cities
Fort Lauderdale, Florida • New Orleans, Louisiana • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 22, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

NCT03003520
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 22, 2026, 9:20 AM EDT
Recruiting Phase 1 Interventional

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT04221542
View directory record Official record
Conditions
Prostate Cancer
Interventions
AMG 509, Abiraterone, Enzalutamide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
25
States / cities
Duarte, California • Fullerton, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

NCT05995405
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions
GTX-104, Nimotop 30 MG Oral Capsule
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 9:20 AM EDT
Not listed Phase 1Phase 2 Interventional

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

NCT03018405
View directory record Official record
Conditions
Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
Interventions
NKR-2 cells
Biological
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Tampa, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 22, 2026, 9:20 AM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 9:20 AM EDT
Withdrawn Not applicable Interventional

Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Management of Pain in Abdominal Non-pancreatic Malignancies

NCT01166529
View directory record Official record
Conditions
Pain, Cancer
Interventions
EUS-guided Celiac Plexus Neurolysis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 22, 2026, 9:20 AM EDT
Not yet recruiting Phase 1 Interventional

64Cu-GRIP B in Patients With Acute Myocarditis

NCT07481136
View directory record Official record
Conditions
Acute Myocarditis
Interventions
64Cu-GRIP B is a radiolabeled peptide tracer, a copper-64 isotope bound to a peptide designed to target extracellular Granzyme B
Drug
Lead sponsor
Javid Moslehi, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 9:20 AM EDT